8-K Announcements
6Material company update
May 8, 2026·SEC
Material company update
Apr 13, 2026·SEC
Material company update
Mar 9, 2026·SEC
Boundless Bio, Inc.(BOLD)Earnings, Financials & Key Ratios
BOLD•NASDAQ
Price updated Jun 19, 2026
AboutBoundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.Show more
- Revenue$0
- EBITDA-$62M+13.7%
- Net Income-$58M+11.0%
- EPS (Diluted)-2.60+32.5%
- ROE-46.69%+91.6%
BOLD Key Insights
Boundless Bio, Inc. (BOLD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.3x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 31.7% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BOLD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BOLD Price & Volume
Boundless Bio, Inc. (BOLD) stock price & volume — 10-year historical chart
Loading chart...
BOLD Growth Metrics
Boundless Bio, Inc. (BOLD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM14.76%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM18.3%
Return on Capital
10 Years-44.55%
5 Years-40.37%
3 Years-46.94%
Last Year-37.08%
BOLD Recent Earnings
Boundless Bio, Inc. (BOLD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (33%)
Q2 2026Latest
May 8, 2026Metric
Actual
Est
EPS
$0.60-4.0%
$0.58
Rev
—
—
Q2 2026
Mar 9, 2026Metric
Actual
Est
EPS
$0.58-31.8%
$0.44
Rev
—
—
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.62-17.0%
$0.53
Rev
—
—
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.70+6.7%
$0.75
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.60vs $0.58-4.0% | — |
| Q2 2026 | Mar 9, 2026 | $0.58vs $0.44-31.8% | — |
| Q4 2025 | Nov 5, 2025 | $0.62vs $0.53-17.0% | — |
| Q3 2025 | Aug 5, 2025 | $0.70vs $0.75+6.7% | — |
Based on last 12 quarters of dataView full earnings history →
BOLD Peer Comparison
Boundless Bio, Inc. (BOLD) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MGNX | 262.52M | 4.13 | -3.50 | 0.78% | -44.79% | -147.8% | 1.92 | |
 TPVG | 202.99M | 5.00 | 4.10 | 36.55% | -19.55% | -3.39% | 1.33 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 IDYA | 2.74B | 31.23 | -24.40 | 30.24% | -62.17% | -13.96% | 0.03 | |
 AUPH | 2.12B | 16.46 | 7.95 | 20.38% | 99.97% | 64.48% | 0.13 | |
 TNGX | 3.25B | 27.97 | -32.15 | 48.29% | -188.15% | -41.54% | 0.10 |
Compare BOLD vs Peers
Boundless Bio, Inc. (BOLD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BOLD Income Statement
Boundless Bio, Inc. (BOLD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 1.09M | 1.25M | 1.22M |
COGS % of Revenue | - | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -1.09M▲ 0% | -1.25M▼ 15.2% | -1.22M▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - | - | - | -15.19% | - |
Operating Expenses | 60.05M | 93.18M | 134.37M | 25.3M | 46.47M | 54.8M | 72.18M | 62.3M | 59.47M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 11.28M | 17.27M | 30M | 6.02M | 9.31M | 12.16M | 18M | 18.71M | 18.25M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
Research & Development | 48.77M | 75.9M | 104.37M | 19.28M | 37.16M | 42.64M | 55.27M | 44.84M | 42.44M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -1.09M | -1.25M | -1.22M |
Operating Income | -60.05M▲ 0% | -93.18M▼ 55.2% | -134.37M▼ 44.2% | -25.3M▲ 81.2% | -46.47M▼ 83.7% | -54.8M▼ 17.9% | -73.27M▼ 33.7% | -63.55M▲ 13.3% | -60.69M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | -55.18% | -44.21% | 81.17% | -83.66% | -17.92% | -33.71% | 13.26% | - |
EBITDA | -58.47M | -89.43M | -126.92M | -24.62M | -45.53M | -53.84M | -72.18M | -62.3M | -59.47M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | -52.96% | -41.92% | 80.6% | -84.93% | -18.26% | -34.07% | 13.69% | 18.07% |
D&A (Non-Cash Add-back) | 1.58M | 3.75M | 7.46M | 682K | 942K | 957K | 1.09M | 1.25M | 1.22M |
EBIT | -60.05M | -93.18M | 0 | -25.3M | -46.47M | -54.8M | -65.36M | -63.55M | -58.03M |
Net Interest Income | 0 | 0 | 0 | 96K | 668K | 5.28M | 7.89M | 5.36M | 4.69M |
Interest Income | 0 | 0 | 0 | 96K | 668K | 5.28M | 7.89M | 5.36M | 4.69M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 378K | 693K | 5.55M | 91K | 568K | 5.36M | 7.9M | 5.36M | 4.69M |
Pretax Income | -59.67M▲ 0% | -92.48M▼ 55.0% | -128.82M▼ 39.3% | -25.21M▲ 80.4% | -45.9M▼ 82.1% | -49.43M▼ 7.7% | -65.36M▼ 32.2% | -58.2M▲ 11.0% | -55.99M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - |
Income Tax | 378K | -2.25M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -0.63% | 2.43% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -59.67M▲ 0% | -90.24M▼ 51.2% | -128.82M▼ 42.8% | -25.21M▲ 80.4% | -45.9M▼ 82.1% | -49.43M▼ 7.7% | -65.36M▼ 32.2% | -58.2M▲ 11.0% | -55.99M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - |
Net Income Growth % | - | -51.23% | -42.76% | 80.43% | -82.07% | -7.7% | -32.22% | 10.96% | 14.76% |
Net Income (Continuing) | -59.67M | -90.24M | -128.82M | -25.21M | -45.9M | -49.43M | -65.36M | -58.2M | -55.99M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -5.59▲ 0% | -3.40▲ 39.2% | -2.93▲ 13.8% | -1.13▲ 61.4% | -2.06▼ 82.3% | -2.22▼ 7.8% | -3.85▼ 73.4% | -2.60▲ 32.5% | -2.50▲ 0% |
EPS Growth % | - | 39.18% | 13.82% | 61.43% | -82.3% | -7.77% | -73.42% | 32.47% | 18.3% |
EPS (Basic) | -1.36 | -2.05 | -2.93 | -1.13 | -2.06 | -2.22 | -3.85 | -2.60 | - |
Diluted Shares Outstanding | 10.67M | 26.58M | 44.03M | 22.24M | 22.24M | 22.24M | 16.98M | 22.36M | 22.41M |
Basic Shares Outstanding | 44.03M | 44.03M | 44.03M | 22.24M | 22.24M | 22.24M | 16.98M | 22.36M | 22.41M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
BOLD Balance Sheet
Boundless Bio, Inc. (BOLD) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 108.44M | 137.01M | 419.77M | 74.57M | 68.04M | 124.2M | 154.39M | 109.61M | 94.62M |
Cash & Short-Term Investments | 104.88M | 133.6M | 414.31M | 73.03M | 66.72M | 120.75M | 152.11M | 107.58M | 92.85M |
Cash Only | 36.36M | 38.97M | 144.35M | 34.29M | 10.95M | 23.71M | 26.59M | 17.87M | 17.48M |
Short-Term Investments | 68.52M | 94.64M | 269.96M | 38.74M | 55.77M | 97.05M | 125.53M | 89.71M | 75.36M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 3.55M | 3.4M | 5.46M | 1.54M | 1.32M | 3.45M | 2.28M | 2.03M | 1.77M |
Total Non-Current Assets | 33.62M | 41.65M | 52.78M | 39.15M | 8.79M | 5.69M | 52.02M | 47.45M | 46.35M |
Property, Plant & Equipment | 18.94M | 24.37M | 32.1M | 3.1M | 7.73M | 4.58M | 51.36M | 46.88M | 45.77M |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 3.63M | 3.63M | 3.63M | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 8M | 8M | 8M | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 34.99M | 0 | 560K | 0 | 0 | 1.12M |
Other Non-Current Assets | 1.84M | 3.09M | 6.43M | 1.07M | 1.07M | 555K | 659K | 573K | 583K |
Total Assets | 142.06M▲ 0% | 178.66M▲ 25.8% | 472.56M▲ 164.5% | 113.72M▼ 75.9% | 76.83M▼ 32.4% | 129.89M▲ 69.1% | 206.41M▲ 58.9% | 157.06M▼ 23.9% | 140.97M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 25.77% | 164.5% | -75.94% | -32.44% | 69.07% | 58.91% | -23.91% | -58.48% |
Total Current Liabilities | 12.56M | 17.71M | 23.85M | 3.87M | 7.73M | 9.36M | 8.13M | 12.54M | 9.58M |
Accounts Payable | 2.42M | 3.85M | 8.12M | 1.07M | 1.4M | 2.22M | 1.27M | 1.49M | 2.04M |
Days Payables Outstanding | - | - | - | - | - | - | 428.19 | 435.02 | 521.13 |
Short-Term Debt | 265K | 4.64M | 2.35M | 0 | 0 | 0 | 0 | 0 | 3.28M |
Deferred Revenue (Current) | 2.97M | 5.56M | 7.72M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 6.9M | 3.65M | 5.67M | 1.51M | 2.55M | 2.9M | 2.78M | 2.64M | 4.26M |
Current Ratio | 8.63x | 7.74x | 17.60x | 19.28x | 8.80x | 13.27x | 18.98x | 8.74x | 9.87x |
Quick Ratio | 8.63x | 7.74x | 17.60x | 19.28x | 8.80x | 13.27x | 18.98x | 8.74x | 9.87x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 7.52M | 6.08M | 10.45M | 148.04M | 150.8M | 247.62M | 47.63M | 45.87M | 45M |
Long-Term Debt | 2.49M | 2.54M | 4.72M | 0 | 0 | 0 | 0 | 0 | 45M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 2.85M | 0 | 47.63M | 45.87M | 140.12M |
Deferred Tax Liabilities | 3.26M | 1.01M | 1.01M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 148.04M | 147.95M | 247.62M | 0 | 0 | 0 |
Total Liabilities | 22.69M | 22.06M | 29.8M | 151.91M | 158.53M | 256.98M | 55.77M | 58.41M | 54.59M |
Total Debt | 2.75M | 7.18M | 7.07M | 377K | 5.18M | 2.19M | 47.63M | 49.03M | 48.29M |
Net Debt | -33.61M | -31.79M | -137.28M | -33.91M | -5.77M | -21.51M | 21.05M | 31.17M | 30.8M |
Debt / Equity | 0.02x | 0.05x | 0.02x | - | - | - | 0.32x | 0.50x | 0.56x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.81x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | -0.52x |
Interest Coverage | - | - | - | - | - | - | - | - | - |
Total Equity | 119.37M▲ 0% | 156.6M▲ 31.2% | 442.75M▲ 182.7% | -38.19M▼ 108.6% | -81.7M▼ 113.9% | -127.08M▼ 55.6% | 150.64M▲ 218.5% | 98.65M▼ 34.5% | 86.38M▲ 0% |
Equity Growth % | - | 31.19% | 182.73% | -108.63% | -113.93% | -55.55% | 218.54% | -34.51% | -136.09% |
Book Value per Share | 11.18 | 5.89 | 10.06 | -1.72 | -3.67 | -5.71 | 8.87 | 4.41 | 3.86 |
Total Shareholders' Equity | 119.37M | 156.6M | 442.75M | -38.19M | -81.7M | -127.08M | 150.64M | 98.65M | 86.38M |
Common Stock | 300M | 300M | 300M | 2K | 0 | 0 | 2K | 2K | 2K |
Retained Earnings | -100.41M | -190.65M | -319.47M | -40.77M | -86.67M | -136.11M | -201.47M | -259.67M | -273.22M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -29K | -80K | -60K | -175K | -398K | 40K | 121K | 64K | -23K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BOLD Cash Flow Statement
Boundless Bio, Inc. (BOLD) cash flow — operating, investing & free cash flow history
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -49.02M | -84.51M | -107.98M | -23.25M | -39.6M | -46.85M | -60.84M | -46.66M | -47.1M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | -72.41% | -27.77% | 78.47% | -70.32% | -18.33% | -29.85% | 23.31% | 82.31% |
Net Income | -59.67M | -90.24M | -128.82M | -25.21M | -45.9M | -49.43M | -65.36M | -58.2M | -55.99M |
Depreciation & Amortization | 1.58M | 3.75M | 7.46M | 682K | 942K | 957K | 1.09M | 1.25M | 1.22M |
Stock-Based Compensation | 2M | 6.88M | 0 | 1.16M | 2.29M | 3.34M | 7.52M | 6.13M | 4.33M |
Deferred Taxes | -95.21M | 2.25M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 7.07M | -30.57M | -279.73M | 959K | 2.21M | -915K | -2.4M | 698K | 2.52M |
Working Capital Changes | 95.21M | 23.42M | 276.62M | -837K | 866K | -799K | -1.68M | 3.46M | 821K |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -671K | 686K | 4.08M | 0 | 1.91M | 0 | 775K | 1.63M | 646K |
Cash from Investing | -62.05M | -33.44M | -185.05M | -59.28M | 16.13M | -38.26M | -26.1M | 37.8M | 49.33M |
Capital Expenditures | -16.65M | -7.55M | -11.61M | -2.03M | -1.07M | -633K | -2.54M | -546K | -495K |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 16K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 75.36M | 120.55M | 398.46M | 105.53M | 126K | 97.9M | 89.82M | 141K | 141K |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 0 | 0 | 105.32M | 126K | 99.67M | 93M | 141K | 141K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -36.36M | -38.97M | -144.35M | 0 | 0 | 0 | 0 | 0 | 117K |
Other Financing | 75.36M | 120.55M | 398.46M | 208K | 0 | -1.77M | -3.18M | 0 | 0 |
Net Change in Cash | -35.7M▲ 0% | 2.61M▲ 107.3% | 105.44M▲ 3942.8% | 22.99M▼ 78.2% | -23.34M▼ 201.5% | 12.78M▲ 154.8% | 2.88M▼ 77.5% | -8.72M▼ 402.6% | 2.37M▲ 0% |
Free Cash Flow | -65.67M▲ 0% | -92.06M▼ 40.2% | -119.59M▼ 29.9% | -25.28M▲ 78.9% | -40.66M▼ 60.8% | -47.49M▼ 16.8% | -63.38M▼ 33.5% | -47.21M▲ 25.5% | -47.6M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - |
FCF Growth % | - | -40.19% | -29.9% | 78.86% | -60.83% | -16.79% | -33.46% | 25.51% | 23.36% |
FCF per Share | -6.15 | -3.46 | -2.72 | -1.14 | -1.83 | -2.14 | -3.73 | -2.11 | -2.12 |
FCF Conversion (FCF/Net Income) | 0.82x | 0.94x | 0.84x | 0.92x | 0.86x | 0.95x | 0.93x | 0.80x | 0.85x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BOLD Key Ratios
Boundless Bio, Inc. (BOLD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -65.4% | -42.99% | -12.46% | - | - | -554.86% | -46.69% | -53.6% |
Return on Invested Capital (ROIC) | -66.37% | -46.84% | -16.26% | - | - | -475.88% | -31.62% | -33.13% |
Debt / Equity | 0.05x | 0.02x | - | - | - | 0.32x | 0.50x | 0.56x |
FCF Conversion | 0.94x | 0.84x | 0.92x | 0.86x | 0.95x | 0.93x | 0.80x | 0.85x |
Related:BOLD Dividend History·BOLD Revenue History·BOLD Price History·BOLD P/E History·BOLD Financial Ratios·BOLD Institutional Holders
BOLD SEC Filings & Documents
Boundless Bio, Inc. (BOLD) SEC filings — annual & quarterly reports (10-K, 10-Q)
BOLD Frequently Asked Questions
Boundless Bio, Inc. (BOLD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Boundless Bio, Inc. (BOLD) grew revenue by 0.0% over the past year. Growth has been modest.
Boundless Bio, Inc. (BOLD) reported a net loss of $56.0M for fiscal year 2025.
Dividend & Returns
Boundless Bio, Inc. (BOLD) has a return on equity (ROE) of -46.7%. Negative ROE indicates the company is unprofitable.
Boundless Bio, Inc. (BOLD) had negative free cash flow of $47.6M in fiscal year 2025, likely due to heavy capital investments.